The mTOR inhibitor rapamycin can strongly inhibit the phosphorylation of S6 and the expression of GLS, and Gln promotes the proliferation of ovarian cancer cells through the mTOR/S6 pathway. Here, GLS is linked to ovarian carcinoma.